Sean Ainsworth
Advisory Board - Biotech CEO
Sean Ainsworth is Immusoft’s Chief Executive Officer and Chairman of the Board. He has more than 25 years’ experience in biotechnology and pharmaceuticals. Previously, he founded and led RetroSense Therapeutics, a gene therapy company he advanced into human clinical trials and sold to Allergan in 2016 in a deal valued at up to $555 million. He also serves as Lead Independent Director at Ocuphire Pharma, a Nasdaq-traded company (OCUP).
Earlier, he was deeply involved in the launch of Compendia Bioscience, Inc., and GeneVivo, LLC. At both he assisted in developing business models, licensing technologies, building management teams, and securing capital and first customers. Compendia was acquired by Life Technologies in 2012.
Sean founded Ainsworth BioConsulting in 2004 to provide licensing, as well as strategic and business planning services to the life science and entrepreneurial community. His clients included large pharma, small biotechs, universities, CROs, and venture investment funds. He has worked with clients at all stages of development. His other professional experience includes research at Medical Biology Institute (now Avanir Pharmaceuticals, developers of Abreva, the leading cold sore medication) in San Diego, Calif., intellectual property at Koyama and Associates in Tokyo, and international corporate development consulting at The Mattson Jack Group (now Kantar Health) in St. Louis, Mo.
Sean earned an M.B.A. in strategy and finance from Washington University in St. Louis. He holds a B.S. in Microbiology from University of California, San Diego.